Effects of phosphodieastrase type 5 inhibitions on morphine withdrawal symptoms in mice

• Autores: Minoo Mahmoodi, Siamak Shahidi, Nasrin Hashemi Firouzi
• Localización: Psicothema, ISSN-e 1886-144X, ISSN 0214-9915, Vol. 26, Nº. 4, 2014, págs. 511-515
• Idioma: inglés
• DOI: 10.7334/psicothema2014.36
• Títulos paralelos:
  • Efectos comportamentales por inhibición de la fosfodiesterasa tipo 5 sobre los síntomas de abstinencia de morfina en ratones
• Enlaces
  • Texto completo (pdf)
• Resumen
  • español

    Antecedentes: se sabe que la exposición crónica a la morfina conduce a la dependencia. El cese en el consumo de morfina conlleva al desarrollo del síndrome de abstinencia. Numerosos estudios indican los efectos beneficiosos del sildenafil en el sistema nervioso central. Es por ello que el presente estudio evaluó el efecto del sildenafil sobre el síndrome de abstinencia a la morfina. Método: los ratones dependientes de morfina recibieron dosis diferentes de sildenafil (1, 5, 10 o 20 mg/kg i.p.) 15 minutos antes de producir el síndrome de abstinencia a la morfina. En el último día, la naloxona se inyectó dos horas después de la última inyección de morfina. Los signos de abstinencia fueron evaluados durante 30 minutos después de la inyección de naloxona. Resultados: la administración de sildenafil redujo todos los síntomas de abstinencia relacionados con la morfina. Conclusiones: se puede concluir que la administración de sildenafil disminuyó los signos de abstinencia a la morfina. Estos resultados muestran cómo los incrementos en el nivel del GMP cíclico mediante la vía PDE5 reduce los síntomas de abstinencia a la morfina.

  • English

    Background:Chronic morphine exposure creates dependence and, upon cessation, withdrawal symptoms. Studies indicate the phosphodiesterase type 5 (PDE5) inhibitor sildenafil may provide centrally mediated benefits against withdrawal, and therefore, this study evaluated morphine withdrawal signs in dependent mice with and without sildenafil treatment. Method: Dependence was induced by repeated treatments with morphine over 5 consecutive days. The morphine-dependent mice received sildenafil (1, 5, 10, or 20 mg/kg, i.p.) 15 min prior to the precipitation of morphine withdrawal. On the last day, naloxone was injected 2 hours after the last morphine injection, and withdrawal signs were evaluated for 30 min after naloxone injection. Results: The administration of sildenafil reduced all of the morphine withdrawal symptoms. Conclusions: The administration of sildenafil diminished morphine withdrawal signs in morphine-dependent mice. We hypothesize that the mechanism involves enhanced cyclic guanosine monophosphate (cGMP) activity, but further studies are recommended for a better understanding

• Referencias bibliográficas
  • Askew, W.E., & Charalampous, K.D. (1976). Effects of morphine administration on cerebellar guanosine 3’,5’-monophosphate. Experientia,...
  • Bhargava, H.N., & Cao, Y.-J. (1997). Effect of chronic administration of morphine, U-50, 488H and [D-Pen 2, D-Pen 5] enkephalin on the...
  • Boccia, M.M., Blake, M.G., Krawczyk, M.C., & Baratti, C.M. (2011). Sildenafil, a selective phosphodiesterase type 5 inhibitor, enhances...
  • Goldstein, I., Lue, T.F., Padma-Nathan, H., Rosen, R.C., Steers, W.D., & Wicker, P.A. (1998). Oral sildenafil in the treatment of erectile...
  • Hamdy, M.M., Mamiya, T., Noda, Y., Sayed, M., Assi, A.A., Gomaa, A., et al. (2001). A selective phosphodiesterase IV inhibitor, rolipram blocks...
  • Jain, N.K., Patil, C.S., Singh, A., & Kulkarni, S.K. (2003). Sildenafil, a phosphodiesterase-5 inhibitor, enhances the antinociceptive...
  • Javadi, S., Ejtemaeimehr, S., Keyvanfar, H.R., Moghaddas, P., Aminian, A., Rajabzadeh, A., et al. (2013). Pioglitazone potentiates development...
  • Koob, G.F., Maldonado, R., & Stinus, L. (1992). Neural substrates of opiate withdrawal. Trends in Neurosciences, 15(5), 186-191.
  • Koob, G.F., Stinus, L., Moal, M.L., & Bloom, F.E. (1989). Opponent process theory of motivation: neurobiological evidence from studies...
  • Kreek, M.J., & Koob, G.F. (1998). Drug dependence: Stress and dysregulation of brain reward pathways. Drug and Alcohol Dependence, 51(1),...
  • Kurt, M., Bilge, S.S., Aksoz, E., Kukula, O., Celik, S., & Kesim, Y. (2004). Effect of sildenafil on anxiety in the plus-maze test in...
  • Lin, C.S. (2004). Tissue expression, distribution, and regulation of PDE5. International Journal of Impotence Research, 16(1), 8-10.
  • Maldonado, R., Dauge, V., Callebert, J., Villette, J.M., Fournie-Zaluski, M.C., Feger, J., et al. (1989). Comparison of selective and complete...
  • McCullough, A.R. (2002). Four-year review of sildenafil citrate. Reviews in Urology, 4(3), 26-38.
  • Mixcoatl-Zecuatl, T., Aguirre-Banuelos, P., & Granados-Soto, V. (2000). Sildenafil produces antinociception and increases morphine antinociception...
  • Mo, Z.X., Leung, W.N., & Yung, K.L. (2005). [Changes in cAMP and cGMP levels in neonatal rat histaminergic neurons of tuberomammillary...
  • Navarro-Zaragoza, J., Núñez, C., Ruiz-Medina, J., Laorden, M.L., Valverde, O., & Milanes, M.V. (2011). CRF(2) mediates the increased noradrenergic...
  • Peregud, D.I., Iakovleva, A.A., Stepanichev, M., Panchenko, L.F., & Guliaeva, N.V. (2013). [Role of NO/cGMP signaling cascade in the development...
  • Prado, J., Pifarre, P., Giralt, M., Hidalgo, J., & García, A. (2013). Metallothioneins I/II are involved in the neuroprotective effect...
  • Prickaerts, J., van Staveren, W.C., Sik, A., Markerink-van Ittersum, M., Niewohner, U., van der Staay, F.J., et al. (2002). Effects of two...
  • Rahimi-Movaghar, A., Amin-Esmaeili, M., Hefazi, M., & Yousefi-Nooraie, R. (2013). Pharmacological therapies for maintenance treatments...
  • Rehni, A.K., Jaggi, A.S., & Singh, N. (2013). Opioid withdrawal syndrome: Emerging concepts and novel therapeutic targets. CNS & Neurological...
  • Shahidi, S., & Hashemi-Firouzi, N. (2014). The effects of a 5-HT7 receptor agonist and antagonist on morphine withdrawal syndrome in mice....
  • Shahidi, S., Hashemi-Firouzi, N., & Mahmoodi, M. (2011). Modulation of Anxiety-Like Behavior in Sildenafil Citrate-Treated Mice Placed...
  • Shahidi, S., Hashemi-Firouzi, N., & Mahmoodi, M. (2013). Coadministration of fluoxetine and Sildenafil has benefits in anxiety behavior...
  • Snyder, S.H., & Bredt, D.S. (1991). Nitric oxide as a neuronal messenger. Trends in Pharmacological Sciences, 12, 125-128.
  • Solis, A.A., Bethancourt, J.A., & Britton, G.B. (2008). Chronic sildenafil (Viagra) administration reduces anxiety in intact and castrated...
  • Tahsili-Fahadan, P., Yahyavi-Firouz-Abadi, N., Orandi, A.H., Esmaeili, B., Basseda, Z., & Dehpour, A.R. (2006). Rewarding properties of...
  • Uthayathas, S., Karuppagounder, S.S., Thrash, B.M., Parameshwaran, K., Suppiramaniam, V., & Dhanasekaran, M. (2007). Versatile effects...
  • Xie, H.Y., Lai, S., Huang, J.C., Jiang, W.Z., Guo, S.C., Huang, R.B., et al. (2008). [Effect of cedemex on cAMP and cGMP levels of different...
  • Yamaguchi, T., Hagiwara, Y., Tanaka, H., Sugiura, T., Waku, K., Shoyama, Y., et al. (2001). Endogenous cannabinoid, 2-arachidonoylglycerol,...
  • Yoon, M.H., Kim, W.M., Lee, H.G., Kim, Y.O., Huang, L.J., & An, T.H. (2008). Roles of opioid receptor subtypes on the antinociceptive...
  • Zhang, R., Wang, Y., Zhang, L., Zhang, Z., Tsang, W., Lu, M., et al. (2002). Sildenafil (Viagra) induces neurogenesis and promotes functional...